MX2008001661A - Methods for treating b-cell malignancies using taci-ig fusion molecule. - Google Patents

Methods for treating b-cell malignancies using taci-ig fusion molecule.

Info

Publication number
MX2008001661A
MX2008001661A MX2008001661A MX2008001661A MX2008001661A MX 2008001661 A MX2008001661 A MX 2008001661A MX 2008001661 A MX2008001661 A MX 2008001661A MX 2008001661 A MX2008001661 A MX 2008001661A MX 2008001661 A MX2008001661 A MX 2008001661A
Authority
MX
Mexico
Prior art keywords
taci
fusion molecule
cell malignancies
treating
methods
Prior art date
Application number
MX2008001661A
Other languages
Spanish (es)
Inventor
Herve Broly
Eric Sievers
Arnaud Ythier
Sharon J Busby
Stephen M Ansell
Jan Ohrstrom
Ivan Nestorov
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of MX2008001661A publication Critical patent/MX2008001661A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BIyS and APRIL.
MX2008001661A 2005-08-09 2006-08-09 Methods for treating b-cell malignancies using taci-ig fusion molecule. MX2008001661A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70691205P 2005-08-09 2005-08-09
PCT/US2006/031277 WO2007019575A2 (en) 2005-08-09 2006-08-09 Methods for treating b-cell malignancies using taci-ig fusion molecule

Publications (1)

Publication Number Publication Date
MX2008001661A true MX2008001661A (en) 2008-04-07

Family

ID=37672215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001661A MX2008001661A (en) 2005-08-09 2006-08-09 Methods for treating b-cell malignancies using taci-ig fusion molecule.

Country Status (15)

Country Link
US (1) US7842292B2 (en)
EP (1) EP1922080A2 (en)
JP (1) JP2009507777A (en)
KR (1) KR20080056714A (en)
CN (1) CN101262876A (en)
AR (1) AR059945A1 (en)
AU (1) AU2006278229B2 (en)
CA (1) CA2618765A1 (en)
EA (1) EA016083B1 (en)
IL (1) IL188403A (en)
MX (1) MX2008001661A (en)
NO (1) NO20081149L (en)
UA (1) UA93516C2 (en)
WO (1) WO2007019575A2 (en)
ZA (1) ZA200801354B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN101489573B (en) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
JP2010530000A (en) * 2007-06-13 2010-09-02 ザイモジェネティクス，インコーポレイティド Dosage method for treating autoimmune disease using TACI-Ig fusion protein such as atacicept
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3211094A3 (en) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
KR20140022815A (en) 2011-02-28 2014-02-25 제넨테크, 인크. Biological markers and methods for predicting response to b-cell antagonists
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
DK368882A (en) 1981-08-25 1983-02-26 Alan John Kingsman EXPESSIONS VECTORS
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4990446A (en) 1984-12-06 1991-02-05 Labofina, S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
ES2092468T3 (en) 1988-01-22 1996-12-01 Zymogenetics Inc METHODS FOR PRODUCING SECRET RECEIVER ANALOGS.
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
EP0514488B1 (en) 1990-02-09 2000-09-13 The Salk Institute For Biological Studies Retinoid receptor compositions and methods
US5208146A (en) 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
CA2144651A1 (en) 1992-09-14 1994-03-31 Timothy J. Miller Immortalized cells and uses therefor
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5650550A (en) 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
US5523227A (en) 1994-06-17 1996-06-04 The Board Of Trustees Of The Leland Stanford Junior Univ. DNA encoding calcium-signal modulating cyclophilin ligand
JP3787355B2 (en) 1994-12-15 2006-06-21 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Modulator of FAS / APO1 receptor function
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19533447C1 (en) 1995-09-09 1996-12-05 Bbs Kraftfahrzeugtechnik Method for filling die with metal melt
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
JP2000500015A (en) 1995-11-09 2000-01-11 ザイモジェネティクス，インコーポレイティド Production of GAD65 in methylotrophic yeast
DK0897390T3 (en) 1996-03-14 2004-03-08 Human Genome Sciences Inc Human tumor necrosis factor delta and epsilon
AU718510B2 (en) 1996-07-17 2000-04-13 Zymogenetics Inc. Transformation of pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
AU708572B2 (en) 1996-07-17 1999-08-05 Zymogenetics Inc. Preparation of (pichia methanolica) auxotrophic mutants
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
JP2002504818A (en) 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド NTN-2 members of the ligand family
WO1998055621A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999012964A2 (en) 1997-09-12 1999-03-18 Biogen, Inc. Kay - a novel immune system protein
EA005411B1 (en) 1997-09-12 2005-02-24 Апотек Р Энд Д Са Use antibody against april polypeptide for preparing medicament for treating tumors
DE19831987A1 (en) 1998-07-16 2000-01-20 Bayer Ag New diphenyl-imidazolines, used as insecticides, acaricides or nematocides, e.g. for plant protection, and as ectoparasiticides
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
JP4787409B2 (en) * 1998-12-30 2011-10-05 レイクウッド−アメディックス，インコーポレーテッド Therapeutic phosphodiesterase inhibitors
TR200101998T2 (en) 1999-01-07 2002-06-21 Zymogenetics, Inc. Soluble receptor BR 43x2 and methods of use
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
PL198934B1 (en) 1999-01-25 2008-08-29 Apoxis Sa Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
NZ513290A (en) 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
WO2000062790A2 (en) 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
DK1180159T3 (en) 1999-05-28 2008-11-17 Targeted Genetics Corp Methods and Compositions to Lower the Level of Tumor Necrosis Factor (TNF) in TNF-Associated Disorders
DK1210425T4 (en) 1999-08-17 2015-08-10 Apotech R & D Sa BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
DK1255558T3 (en) * 2000-02-16 2006-10-23 Genentech Inc Anti-April antibodies and hybridoma cells
AU2006201471B2 (en) 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
ES2528794T3 (en) 2000-04-11 2015-02-12 Genentech, Inc. Multivalent antibodies and uses thereof
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
DK1297013T3 (en) * 2000-04-27 2006-12-27 Biogen Idec Inc Use of TACI as antitumor agent
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
KR100886276B1 (en) 2000-08-11 2009-03-04 기린 파마 가부시끼가이샤 Polypeptides Controlling Phosphoric Acid Metabolism, Calcium Metabolism, Calcification and Vitamin D Metabolism and DNAs Encoding the Same
US20030092164A1 (en) 2000-11-07 2003-05-15 Gross Jane A. Human tumor necrosis factor receptor
SI1436003T1 (en) 2001-05-24 2010-02-26 Zymogenetics Inc Taci-immunoglobulin fusion proteins
WO2003014294A2 (en) 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
MXPA06004301A (en) 2003-10-20 2006-06-05 Biogen Idec Inc Therapeutic regimens for baff antagonists.
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules

Also Published As

Publication number Publication date
EP1922080A2 (en) 2008-05-21
WO2007019575A2 (en) 2007-02-15
AU2006278229B2 (en) 2011-10-27
AU2006278229A1 (en) 2007-02-15
WO2007019575A3 (en) 2007-06-21
IL188403A0 (en) 2008-08-07
JP2009507777A (en) 2009-02-26
KR20080056714A (en) 2008-06-23
CA2618765A1 (en) 2007-02-15
NO20081149L (en) 2008-04-30
AR059945A1 (en) 2008-05-14
CN101262876A (en) 2008-09-10
US20070071760A1 (en) 2007-03-29
IL188403A (en) 2011-06-30
EA200800560A1 (en) 2008-06-30
UA93516C2 (en) 2011-02-25
EA016083B1 (en) 2012-02-28
US7842292B2 (en) 2010-11-30
ZA200801354B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
UA93516C2 (en) Methods for treating b-cell malignancies using taci-ig fusion molecule
SG164368A1 (en) Treatment of cancer
MXPA02010801A (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites.
MX349188B (en) Sns-595 and methods of using the same.
TW200503674A (en) Therapeutic agents
TW200504053A (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
TW200738735A (en) Oxygen linked pyrimidine derivatives
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
HK1120427A1 (en) Anti-glypican-3 antibody
TW200637836A (en) Cytotoxic agents comprising new taxanes
GB2442915B (en) Perylenequinone derivatives and uses thereof
MX2007004955A (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally.
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
SI1763356T1 (en) Composition comprising a survivin antisense oligonucleotide and gemcitabine for the treatment of cancer
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
MXPA05007462A (en) Pyrrolopyridazine derivatives.
TW200640893A (en) Cytotoxic agents comprising new C-2 modified taxanes
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
DE60036915D1 (en) USE OF HYALURONAN FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING THE EFFICACY OF CYTOTOXIC DRUGS
WO2007134326A3 (en) Methods for treating autoimmune diseases using a taci-ig fusion molecule
UA72927C2 (en) Docetaxel-containing composition for treating hepatocellular carcinoma
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007019573A3 (en) Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules

Legal Events

Date Code Title Description
FG Grant or registration